Compare OI & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OI | SUPN |
|---|---|---|
| Founded | 1903 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.6B |
| IPO Year | N/A | 2012 |
| Metric | OI | SUPN |
|---|---|---|
| Price | $15.18 | $48.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $16.29 | ★ $63.25 |
| AVG Volume (30 Days) | ★ 2.5M | 658.9K |
| Earning Date | 02-03-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,455,000,000.00 | $681,539,000.00 |
| Revenue This Year | $1.41 | $8.32 |
| Revenue Next Year | $1.99 | $23.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $9.23 | $29.16 |
| 52 Week High | $16.04 | $57.65 |
| Indicator | OI | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 66.54 | 59.46 |
| Support Level | $15.00 | $45.36 |
| Resistance Level | $15.72 | $47.26 |
| Average True Range (ATR) | 0.46 | 1.23 |
| MACD | 0.12 | 0.51 |
| Stochastic Oscillator | 78.78 | 88.31 |
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.